Clinical Trials Browser

Phase 3 × Not yet recruiting × Carcinoma, Non-Small-Cell Lung × Clear all

NCT07388524 2026-04-17

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07513376 2026-04-07

INTerpath-014

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07477808 2026-03-23

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07464327 2026-03-11

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07442565 2026-03-04

SYNSTAR03

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07416474 2026-02-20

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07416994 2026-02-18

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07361484 2026-01-23

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07242274 2025-11-21

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07197853 2025-09-29

HAMSTER

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07154368 2025-09-19

JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07162883 2025-09-09

Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)

Phase 3 Not yet recruiting

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Lymphatic Metastasis, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07135882 2025-08-22

PRIME-Lung

Phase 3 Not yet recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06955325 2025-05-06

UPLIFT

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06828757 2025-02-19

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06704620 2024-12-16

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06254599 2024-02-12

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05990127 2023-08-14

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05767892 2023-04-05

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04772287 2021-02-26

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04465968 2020-07-10

DEEP_OCEAN

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Pancoast Syndrome